Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iclaprim - Motif Bio

Next Previous
Drug Profile

Iclaprim - Motif Bio

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 28 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio; Otto von Guericke University Magdeburg
  • Class Amines; Anti-infectives; Antibacterials; Antiprotozoals; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Skin and soft tissue infections
  • Phase II Nosocomial pneumonia; Ventilator associated pneumonia
  • No development reported Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections; Staphylococcal infections; Toxoplasmosis
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 28 Aug 2023 No recent reports of development identified for preclinical development in Staphylococcal-infections(In children) in United Kingdom
  • 28 Jun 2023 No recent reports of development identified for preclinical development in Toxoplasmosis in United Kingdom
  • 28 Aug 2022 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in United Kingdom (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top